Federal Bid

Last Updated on 21 Feb 2007 at 5 AM
Sources Sought
Pittsburgh Pennsylvania

65--65 -- IDI-MRSA TESTS

Solicitation ID 244-07-01765
Posted Date 12 Jan 2007 at 5 AM
Archive Date 21 Feb 2007 at 5 AM
NAICS Category
Product Service Code
Set Aside No Set-Aside Used
Contracting Office 244-Network Contract Office 4 (36c244)
Agency Department Of Veterans Affairs
Location Pittsburgh Pennsylvania United states 15240
The VA Pittsburgh Healthcare System intends to negotiate on a sole source basis with BD GeneoHm, 6146 Nancy Ridge Drive, San Diego, CA 92121 for the BD GeneOhm MRSA assays. The BD GeneOhm MRSA (IDI-MRSA) test from BD GeneOhm Inc. is the only rapid, molecular-based assay cleared by the FDA and bearing the CE Mark for the direct detection of methicillin-resistant Staphylococcus aureus (MRSA) from a nasal specimen. This assay is a qualitative in-vitro diagnostic test for the direct detection of nasal colonization by methicillin-resistant Staphyloccus aureus (MRSA) to aid in the prevention and control of MRSA infections in healthcare settings. The test performed on the Smart Cycle 2 instrument with a nasal swab specimen from patients at risk for colonization, utilizes polymerase chain reaction (PCR) for the amplification of MRSA DNA and fluorogenic target- hybridization probes for the detection of the amplified DNA. The test provides a definitive result with an assay time of less than two hours. The BD GeneOhm™ MRSA test detects a unique molecular sequence which confers a double specificity: half of this sequence comes from the S. aureus chromosome; the second half is within the genetic element carrying methicillin resistance, the SCCmec cassette. The test detects the SCCmec sequence using a specific protocol. The BD GeneOhm™ MRSA test kit is composed of the following assay specific reagents, which when used with the above protocol and the Smart Cycler® 2 instrument provide a definitive result within two hours. Sample buffer Tris-EDTA buffer Lysis tube Glass beads Master mix < 0.0005 % DNA polymerase complex < 0.001% Internal Control - non-infectious DNA containing MRSA-primer binding sequences and a unique sequence for probe hybridization < 0.002 % primers < 0.002 % molecular probes < 0.05 % dATP, dCTP, dGTP, dTTP Bovine serum albumin Carbohydrate MgCl2 < 0.001 % non-infectious Staphylococcus epidermidis genomic DNA (ATCC 14990) Control DNA Tris-EDTA buffer Carbohydrate < 0.001 % non-infectious genomic MRSA DNA (ATCC 43300) Diluent Tris-HCl buffer MgCl2 (NH4)2SO4 KCl This Notice of Intent is NOT a request for competitive proposals. Vendors who wish to identify their interest and capability to provide an MRSA test assay compatible with the Smart Cycle 2 as described above, may notify the Contracting Officer, in writing, no later than 9:00 A.M. on January 22, 2007. Such notification must include a complete description of proposed test assays, including narrative and capabilities described above. Responses may be sent to [email protected] or mailed to Kathleen Policicchio, Contracting Officer, (04A1-H), VA Pittsburgh Healthcare System, 7180 Highland Drive, Pittsburgh, PA 15206. Information received will be for the purpose of determining whether or not to conduct a competitive procurement or proceed with sole source negotiations. The determination to conduct a competitive procurement based on responses to this notice is solely within the discretion of the VAPHS Contracting Officer.
Bid Protests Not Available

Similar Past Bids

Location Unknown Not Specified
Location Unknown 17 Mar 2004 at 5 AM
Location Unknown 07 Apr 2004 at 5 AM
Independence West virginia 24 Aug 2015 at 2 PM
Los angeles California 24 Dec 2020 at 5 AM

Similar Opportunities

Pennsylvania 28 Jul 2025 at 4 AM (estimated)
Pennsylvania 28 Jul 2025 at 4 AM (estimated)
Cincinnati Ohio 31 Oct 2025 at 4 AM (estimated)